CAR based immunotherapy of solid tumours – a survey of the emerging targets.

John Maher; David Davies

doi:10.3390/cancers15041171

CAR based immunotherapy of solid tumours – a survey of the emerging targets.

John Maher, David Davies

Comprehensive Cancer Centre

Leucid Bio Ltd

Research output: Contribution to journal › Review article › peer-review

10 Citations (Scopus)

Abstract

Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers. However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a partner review, we have surveyed data generated in clinical trials in which patients with solid tumours that expressed any of 30 discrete targets were treated with CAR-based immunotherapy. That exercise confirms that efficacy of this approach falls well behind that seen in haematological malignancies, while significant toxic events have also been reported.
Here, we consider approximately 60 additional candidates for which such clinical data are not available yet, but where pre-clinical data have provided support for their advancement to clinical evaluation as CAR target antigens.

Original language	English
Article number	1171
Pages (from-to)	1171
Number of pages	30
Journal	Cancers
Volume	15
Issue number	4
DOIs	https://doi.org/10.3390/cancers15041171
Publication status	Published - 11 Feb 2023

Keywords

solid tumour
chimeric antigen receptor
T-cell
NK cell
target
toxicity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers15041171

https://www.mdpi.com/2072-6694/15/4/1171Licence: CC BY

Cite this

@article{232f058a4c8d4c3385985590fa9d8a89,

title = "CAR based immunotherapy of solid tumours – a survey of the emerging targets.",

abstract = "Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers. However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a partner review, we have surveyed data generated in clinical trials in which patients with solid tumours that expressed any of 30 discrete targets were treated with CAR-based immunotherapy. That exercise confirms that efficacy of this approach falls well behind that seen in haematological malignancies, while significant toxic events have also been reported.Here, we consider approximately 60 additional candidates for which such clinical data are not available yet, but where pre-clinical data have provided support for their advancement to clinical evaluation as CAR target antigens.",

keywords = "solid tumour, chimeric antigen receptor, T-cell, NK cell, target, toxicity",

author = "John Maher and David Davies",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = feb,

day = "11",

doi = "10.3390/cancers15041171",

language = "English",

volume = "15",

pages = "1171",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "4",

}

TY - JOUR

T1 - CAR based immunotherapy of solid tumours – a survey of the emerging targets.

AU - Maher, John

AU - Davies, David

PY - 2023/2/11

Y1 - 2023/2/11

N2 - Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers. However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a partner review, we have surveyed data generated in clinical trials in which patients with solid tumours that expressed any of 30 discrete targets were treated with CAR-based immunotherapy. That exercise confirms that efficacy of this approach falls well behind that seen in haematological malignancies, while significant toxic events have also been reported.Here, we consider approximately 60 additional candidates for which such clinical data are not available yet, but where pre-clinical data have provided support for their advancement to clinical evaluation as CAR target antigens.

AB - Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers. However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a partner review, we have surveyed data generated in clinical trials in which patients with solid tumours that expressed any of 30 discrete targets were treated with CAR-based immunotherapy. That exercise confirms that efficacy of this approach falls well behind that seen in haematological malignancies, while significant toxic events have also been reported.Here, we consider approximately 60 additional candidates for which such clinical data are not available yet, but where pre-clinical data have provided support for their advancement to clinical evaluation as CAR target antigens.

KW - solid tumour

KW - chimeric antigen receptor

KW - T-cell

KW - NK cell

KW - target

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=85149136300&partnerID=8YFLogxK

U2 - 10.3390/cancers15041171

DO - 10.3390/cancers15041171

M3 - Review article

SN - 2072-6694

VL - 15

SP - 1171

JO - Cancers

JF - Cancers

IS - 4

M1 - 1171

ER -

CAR based immunotherapy of solid tumours – a survey of the emerging targets.

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this